Recludix develops a drug discovery platform that utilizes custom DNA-encoded libraries and a proprietary screening tool to identify selective inhibitors targeting SH2 domains, which are implicated in inflammatory diseases. The company focuses on creating STAT6 and STAT3 inhibitors to address abnormal protein activation in conditions such as rheumatoid arthritis and asthma.
Funding
$60M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Inflammatory diseases are often driven by abnormal protein activation mediated by SH2 domains. These domains regulate protein activity and location, and when dysregulated, can lead to cellular responses that contribute to inflammatory disorders. Traditional drug discovery methods struggle to identify selective inhibitors targeting these SH2 domains.
Solution
Recludix develops a drug discovery platform focused on identifying selective inhibitors targeting SH2 domains to treat inflammatory diseases. The platform utilizes custom DNA-encoded libraries and a proprietary screening tool to identify molecules that can modulate SH2 domain activity. By targeting specific SH2 domains, such as those associated with STAT3 and STAT6 proteins, Recludix aims to address the underlying causes of inflammation in diseases like rheumatoid arthritis and asthma. The platform is designed to overcome the challenges of traditional methods and unlock new therapeutic possibilities.
Target Audience
Recludix's primary target audience includes pharmaceutical companies and research institutions focused on developing novel therapies for inflammatory diseases.
Features
- Custom DNA-encoded libraries for generating a diverse range of potential inhibitors.
- Proprietary screening tool for identifying selective inhibitors of SH2 domains.
- Focus on STAT3 and STAT6 proteins, key mediators of inflammation.
- Ability to target biologically-validated targets previously considered elusive.